<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04817527</url>
  </required_header>
  <id_info>
    <org_study_id>XJTU1AF2021LSK-065</org_study_id>
    <nct_id>NCT04817527</nct_id>
  </id_info>
  <brief_title>Edaravone Dexborneol for Treatment of Acute Ischemic Stroke With Endovascular Therapy in Extended Time Windows</brief_title>
  <acronym>EXISTENT</acronym>
  <official_title>Edaravone Dexborneol for Treatment of Acute Ischemic Stroke With Endovascular Therapy in Extended Time Windows (EXISTENT):a Prospective, Randomized, Open-label, Multi-centre Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital Xi'an Jiaotong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First Affiliated Hospital Xi'an Jiaotong University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To explore the safety and efficacy of edaravone dexborneol for patients of acute ischemic&#xD;
      stroke received endovascular therapy in extended time windows.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with modified Rankin Score 0 to 3 on day 90</measure>
    <time_frame>90 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of symptomatic intracranial hemorrhage (sICH)</measure>
    <time_frame>48 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>mTICI grade (&lt;2 b、≥2 b) stratified for primary outcome analysis</measure>
    <time_frame>90 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in National Institute of Health stroke scale (NIHSS) on day 2,7,14</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of modified Rankin Score after the treatment</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in infarct volume</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients with Barthel Index (BI) score greater than or equal to 95 on day 14, 30, 90</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activity of Daily Living Scale(ADL) score on day 14, 30, 90</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Montreal Cognitive Assessment(MoCA) score on day 14, 30, 90</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum inflammatory factors changes on day 1 and day 7</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of PH1 and PH2 within 48 hours after the treatment</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Midline shift on the CT scan</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of death due to any cause</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Serious adverse events(SAE)</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Stroke, Ischemic</condition>
  <arm_group>
    <arm_group_label>Edaravone Dexborneol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>conventional therapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>conventional therapy of acute ischemic stroke after Endovascular Therapy based on Chinese guidelines for endovascular therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Edaravone Dexborneol</intervention_name>
    <description>Intravenous injections of edaravone dexborneol (37.5mg in 0·9% NaCl) BID for 7-14days.</description>
    <arm_group_label>Edaravone Dexborneol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18 to 80 years of age;&#xD;
&#xD;
          2. Acute ischemic stroke with National Institute of Health Stroke Scale (NIHSS) ≥ 10 and&#xD;
             Volume of infarction on DWI &lt;31ml or with a NIHSS ≥20 and 31ml&lt;Volume of&#xD;
             infarction&lt;51ml(DWI);&#xD;
&#xD;
          3. Patients who presented with acute ischemic stroke and a large vessel occlusion in the&#xD;
             anterior circulation;&#xD;
&#xD;
          4. Endovascular Therapy in 6-24 hours of stroke onset;&#xD;
&#xD;
          5. The availability of informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. First ever stroke or mRS≤1 after previous disease;&#xD;
&#xD;
          2. Hemorrhagic stroke: cerebral hemorrhage, subarachnoid hemorrhage;&#xD;
&#xD;
          3. Coagulation disorders, systematic hemorrhagic tendency, thrombocytopenia&#xD;
&#xD;
          4. Severe hepatic or renal dysfunction, increase in ALT or AST (more than 2 times of&#xD;
             upper limit of normal value), increase in serum creatinine (more than 1.5 times of&#xD;
             upper limit of normal value) or requiring dialysis;&#xD;
&#xD;
          5. Severe cardiac or pulmonary disease;&#xD;
&#xD;
          6. Patients with malignant tumor or under antineoplastic therapy with estimated lifetime&#xD;
             less than 3 months;&#xD;
&#xD;
          7. Pregnancy, plan to get pregnant or during lactation;&#xD;
&#xD;
          8. Patients with contraindication or allergic to any ingredient of drugs in our study;&#xD;
&#xD;
          9. Unsuitable for this clinical studies assessed by researcher&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jianfeng Han, MD</last_name>
    <phone>+8618991232708</phone>
    <email>rabbit1110@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ying Tan, MD</last_name>
    <phone>+8613581693768</phone>
    <email>13581693768@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>First Affiliated Hospital of Xian Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 25, 2021</study_first_submitted>
  <study_first_submitted_qc>March 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2021</study_first_posted>
  <last_update_submitted>August 23, 2021</last_update_submitted>
  <last_update_submitted_qc>August 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Endovascular therapy</keyword>
  <keyword>Extended Time Windows</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edaravone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

